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(range 18-71) and 59% were males. Intensity of conditioning
regimens was: conventional, 243 (80%); reduced/minimal, 59
(20%). Prior to BMT, 40 patients had received Imatinib and 21
(7%) had a signiﬁcant neurological history: CNS involvement by
primary disease, 12; history of CVA/TIA, 4; seizures, 5.
The cumulative incidence of neurological complications at 30,
100, 180 and 365 days was 9%, 18%, 20% and 23%, respectively.
Manifestations of neurological complications within 100 days
(n53) of transplant were seizures (n19), visual disturbances
(n9), altered level of consciousness (n7), confusion/delirium
(n11) and others (n7). For the patients surviving 100 days
(n255), 17 developed neurological complications manifesting as
seizures (n3), altered level of consciousness (n1), visual distur-
bance (n4), confusion/delirium (n7) and others (n2). Of the
22 patients with seizures, the etiology was posterior reversible
encephalopathy syndrome (PRES) in 15 (68%). Of the 21 patients
with signiﬁcant neurological history prior to BMT, 4 developed
seizures.
Multivariate regression analysis identiﬁed female gender and
high-dose total-body irradiation (TBI) containing conditioning
regimens as the independent risk factors for neurological compli-
cations in ﬁrst 100 days of transplant (Table 1).
Survival at 1-year was signiﬁcantly inferior in patients who de-
veloped neurological complications in ﬁrst 100 days of transplant
compared to those who did not (27% versus 71%, p0.0001).
We conclude that neurological complications in ﬁrst 100 days
have a signiﬁcantly adverse impact on survival in the recipients of
AlloHCT. High-dose TBI containing conditioning regimens
should be avoided in the patients considered at a higher risk for
neurological complications.
Table 1. Multivariate Regression analysis for risk factors for
neurological complications in ﬁrst 100 days of transplant
Variable Comparison
Odds
ratio
95% Confidence
Intervals (C.I.) p-value
Gender Female Vs. Male 2.03 1.08-3.84 0.03
Imatinib prior
to BMT
No Vs. Yes 0.48 0.22-1.06 0.07
Intensity of
Conditioning
Conventional
versus Reduced /
Minimal
2.23 0.69-7.19 0.18
Dose of TBI in
the
conditioning
regimen
None Vs. High dose
(1200 cGy) / Low/
Mod (200-500
cGy) Vs. High
dose (1200 cGy)
0.29/0.62 0.12-0.73 / 0.27-
1.41
0.03
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MIXED CHIMERISM (MC) AFTER STANDARD ALLO STEM CELL TRANS-
PLANTATION (SCT) IN CHILDREN: 1) CAN MC BE USED AS A PREDIC-
TOR OF RELAPSE? 2) WHEN DOES MC BECOME STABLE AFTER TRANS-
PLANT OF NON-MALIGNANT PATIENTS?
Heilmann, C.1, Madsen, H.O.2, Muller, K.G.1, Jacobsen, N.1 1Bone
Marrow Transplant Unit, Rigshospitalet, University Hospital, Copen-
hagen, Denmark; 2Tissue Typing Laboratory, Rigshospitalet, University
Hospital, Copenhagen, Denmark.
The purpose of this investigation was to evaluate: 1) Whether the
presence of MC early in the post SCT course is a risk factor for
later relapse. 2) To examine in non-malignant diseases when MC
becomes stable after SCT.
Patients and methods: MC was determined by PCR based ana-
lyzes of microsatellite polymorphisms. The level of sensitivity of
this method is approximately 1% residual recipient cells. All (N:
74) children transplanted for leukaemia or MDS between 97.10.20
and 05.09.01 were examined consecutively for the presence of MC.
An initial analysis of the MC courses revealed three main patterns:
1) Early MC (d90), 2) Late MC (d90) and 3) MC as an
integrated part of an ongoing histiological veriﬁed relapse. We
have evaluated associations between early as well as late MC and
the occurence of later relapse.
Furthermore, MC was examined in patients transplanted for
non-malignant disease (N: 25). Only patients who had at least
one examination showing MC and who had measurements of
MC at least one year post SCT were included in this evaluation.
MC were examined on 11 occations (mean, range: 3-29). The
last examination was 3.1 years (mean, range: 1.2-5.8) after trans-
plant.
Results. Among leukaemia patients (N: 24) who later relapsed
34% showed signs of early MC whereas, 35% of leukaemia patients
(N: 50) who did not relapse showed signs of early chimerism. Late
MC was observed in 25% of patients who relapsed and among 22%
of patients who did not relapse. Similarly, when ALL patients were
examined separately (N: 47) no signiﬁcant difference in MC (early
or late) was recorded between patients who later relapsed and those
who didnt.
Patients with MC transplanted for non-malignant diseases in
average showed constant MC levels 0.49 years (mean, range: 0.05-
1.83) after transplant.
Conclusion. 1) In paediatric patients with leukaemia the pres-
ence of MC is not associated with recurrence if the MC is not an
integrated part of a histiological relapse. 2) In patients with early
MC, one half of these achieve a stable level of chimerism within
the ﬁrst 0.5 year and maintaine this level thereafter. Signiﬁcant
changes are rare after 1.8 years post transplant.
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IMPACT OF 100-DAY SURVIVAL ON LONG-TERM OUTCOME OF MY-
ELOABLATIVE TRANSPLANT AT AN EARLY STAGE OF LEUKEMIA
Hiraoka, A.1 1Osaka Medical Center for Cancer and CVD, Osaka,
Japan.
Objective; There is a growing demand for quality improvement
in hemtopoietic stem cell transplantation (HSCT) as in other ﬁelds
of patient management. An indicator(s) is necessary for the quality
assurance, which ﬁnally leads a continuous quality improvement
process. We analyzed the impact of survival rate at 100 days
post-transplant (100-day S)on the long-term outcome in leukemia
patients who received a myeloablative HSCT at an early stage of
leukemia.
Methods; Two databases were used; one from our hospital (1),
and one from Japan Marrow Donor Program Registry (JMDPR)
(2). (1) Total 229 patients who received a transplant at 1st CP of
CML or 1st or 2nd CR of acute leukemia at our hospital were
divided into two groups; 65 patients who received a related
transplant before 1988 or unrelated transplant before 1997
(group E) and the remaining 164 patients (group L). (2) Total
1,203 patients received an unrelated transplant via JMDPR at 1st
CP or 1st CR from 1993 to 2001. Number of hospital which
performed at least 10 transplants was 40. Among these 40
hospitals, 6 hospitals showed a signiﬁcantly lower 100-day S
than the average of all of 1,203 patients. Total 125 patients
received a transplant at these 6 hospitals (group B) and total 697
patients at the remaining 34 hospitals (group G).
Results; (1) The 100-day S was 83.1% in group E and 95.7% in
group L (p0.001). Overall survival (OS) at 5 years was 62.5% in
group E and 74.6% in group L (p0.049). OS at 5 years of
survivors over 100 days post-transplant was 74.1% in group E and
78.4% in group L (p0.54). (2) The 100-day S was 66.4% in group
B and 89.6% in group G (p0.001). OS at 10 years was 47.0% in
group B and 59.7% in group G (p0.001). OS at 10 years of
survivors over 100 days post-transplant was 70.8% in group B and
66.3% in group G (p0.68).
Conclusions; In these two patient populations, patient groups
with a lower 100-day S showed a worse long-term outcome. Sur-
vivors over 100 days post-transplant in both patient groups showed
a similar long-term outcome. Thus the 100-day S might be an
indicator for the quality assurance of myeloablative HSCT at an
early stage of leukemia.
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